• Strategic Advances in Translational Apoptosis & Pyroptosis R

  2026-06-04

  Explore how mechanistic insight and next-generation detection technologies—centered on the One-step TUNEL Cy3 Apoptosis Detection Kit—are redefining the landscape of translational research into apoptosis and pyroptosis. This article bridges foundational cell death biology, advanced assay design, and real-world clinical relevance, with a forward-looking perspective on hepatic carcinoma therapy and immune modulation.

• OTC-Regulated Ornithine Drives Realgar-Induced CNS Toxicity

  2026-06-04

  This study reveals how realgar-derived arsenic impairs hepatic OTC, causing ornithine accumulation that activates ZBTB7A-mediated repression of astrocyte glycolysis along the liver–brain axis. These mechanistic findings clarify the molecular link between urea cycle disruption and CNS injury, with implications for metabolic neurotoxicity research.

• Coumestrol in RA: Beyond Estrogen Receptor Antagonism

  2026-06-03

  Explore how Coumestrol, a potent phytoestrogen estrogen receptor antagonist, drives ferroptosis in rheumatoid arthritis synoviocytes via novel mitochondrial pathways. This article delivers a unique mechanistic deep dive and practical guidance for advanced SERM studies.

• Optimized hiPSC Platelet Differentiation: Protocol and Impli

  2026-06-03

  This study presents a systematically optimized protocol for deriving functional platelets from human induced pluripotent stem cells (hiPSCs), addressing major challenges of yield, cost, and functional maturation. The approach integrates refined culture conditions and selective small-molecule modulators, offering a scalable and cost-effective advancement for both research and potential clinical applications.

• PA-824: Bicyclic Nitroimidazole Derivative in TB Research

  2026-06-02

  PA-824 empowers tuberculosis research with its potent, dual-mechanism bactericidal activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis strains. Leveraging its in vitro synergy with respiratory chain inhibitors, researchers can design advanced combination assays and accelerate anti-TB drug discovery with high reproducibility.

• BX795: Precision PDK1 Inhibitor for Immune and Cancer Resear

  2026-06-02

  BX795 empowers researchers to dissect PI3K/Akt/mTOR and innate immune pathways with nanomolar precision, offering unique leverage in cancer and antiviral studies. Recent breakthroughs reveal its central role in unraveling hepatitis B immune evasion, making BX795 an indispensable tool for translational discovery.

• Applied Protocols with SU5416 (Semaxanib): Angiogenesis and

  2026-06-01

  SU5416 (Semaxanib) is a selective VEGFR2 inhibitor with dual anti-angiogenic and immunomodulatory properties, unlocking precise control over tumor vascularization and immune mechanisms in preclinical models. This guide delivers actionable protocols, troubleshooting, and a translational bridge to pulmonary hypertension research, leveraging APExBIO's trusted formulation for reproducible, high-impact results.

• Lactobacillus gasseri Modulates Colitis via NR1I3 and E-cadh

  2026-06-01

  This study uncovers how Lactobacillus gasseri ATCC33323 ameliorates DSS-induced colitis in mice by regulating intestinal epithelial barrier function through NR1I3-mediated transcriptional control of E-cadherin. These findings provide mechanistic insight into probiotic therapy for IBD and establish the importance of E-cadherin in gut mucosal protection.

• Chenodeoxycholic Acid: FXR–KLF11 Axis in Renal and Metabolic

  2026-05-31

  Unlock the unique role of Chenodeoxycholic Acid in regulating the FXR–KLF11 axis for advanced cholesterol metabolism and renal protection studies. Explore mechanistic insights and protocol strategies not found in standard CDCA reviews.

• SU5416 (Semaxanib): Mechanistic Insights and New Horizons in

  2026-05-30

  Explore the unique dual mechanism of SU5416 (Semaxanib) in inhibiting VEGF-induced angiogenesis and modulating immune responses. This in-depth article reveals advanced protocol strategies, practical implications from biomarker research, and how SU5416 enables next-generation cancer and vascular studies.

• ICOS Signaling Drives Th2 Differentiation in Allergic Rhinit

  2026-05-29

  This study demonstrates that inducible co-stimulator (ICOS) signaling promotes the differentiation of Th2 cells in allergic rhinitis (AR), linking ICOS-expressing Th2 cells to disease severity and response to immunotherapy. The findings provide mechanistic insight into T cell subset dynamics during AR and identify ICOS as a potential biomarker and therapeutic target.

• BKT140 (BL-8040): Applied CXCR4 Antagonism in Oncology Workf

  2026-05-29

  BKT140 (BL-8040) empowers oncology researchers to precisely inhibit CXCR4-mediated tumor migration and mobilize hematopoietic stem cells, making it a linchpin for translational cancer studies. This guide details experimental best practices, troubleshooting tactics, and workflow enhancements that maximize BKT140’s impact in both solid and hematologic tumor models.

• Amphotericin B as a Membrane Probe: Mechanistic Insights for

  2026-05-28

  Explore Amphotericin B’s dual role as a polyene antifungal antibiotic and a membrane-disrupting probe, with a focus on its mechanism of action, immune modulation, and unique guidance for rigorous fungal infection research. Discover nuanced insights not found in conventional reviews.

• Sulfaphenazole: Precision CYP2C9 Inhibitor for Translational

  2026-05-28

  Sulfaphenazole enables highly selective CYP2C9 inhibition, empowering researchers to modulate drug metabolism and restore vascular function under oxidative stress. Its proven efficacy in tissue protection and antibacterial activity makes it a versatile tool from in vitro assays to animal models.

• Sulfaphenazole: Advanced Insights into CYP2C9 Inhibition and

  2026-05-27

  Explore Sulfaphenazole as a CYP2C9 inhibitor with unique dual roles in drug metabolism studies and anti-tuberculosis research. This article delivers an in-depth perspective grounded in recent structure–activity optimization findings, revealing new directions for assay design and therapeutic innovation.

16894 records 1/1127 page Next 12345 下5页 Last page